DelveInsight’s ‘Migraine Market Insights, Epidemiology and Market Forecast—2032’ report delivers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Migraine market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted Migraine symptoms market size from 2019 to 2032 segmented by the seven major markets. The report also covers current Migraine symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Some of the key facts of the Migraine Market:
Got queries? Click here to know more about the Migraine market landscape
Migraine, a primary headache disorder, is a neurological condition that causes multiple symptoms frequently characterized by intense, debilitating headaches. It often runs in families and affects all ages. It is of majorly two types: acute and chronic migraine. The exact cause of migraine is unknown, but they are thought to be the result of abnormal brain activity temporarily affecting nerve signals, chemicals, and blood vessels in the brain. Many possible migraine triggers have been suggested, including hormonal, emotional, physical, dietary, environmental, and medicinal factors. These triggers vary among individuals, but a diary may help keep track of consistent triggers.
With the first CGRP inhibitor approved in 2018, there have been many new approvals, offering a significant boost in migraine market growth. In September 2021, FDA approved QULIPTA (atonement) for the preventive treatment of episodic migraine in adults. CGRP drugs (both oral and injectables) are proving to be revolutionary in the migraine market with huge advantages over traditional generic antidepressants, antihypertensives, etc. The migraine market size is anticipated to significantly grow during the study period, 2019–2032 owing to the robust pipeline of novel therapies like CGRP inhibitors, approval and launch of competitive products, increasing awareness to treat/prevent migraine, increasing access due to improving reimbursements from payers. However, premium pricing of drugs, market access, and reimbursement challenges, are likely to complicate market success. Some of the therapies in the pipeline are, Zavegepant (Biohaven Pharmaceutical), AXS-07 (Axsome Therapeutics), and ABP-450 (AEON Biopharma) among others.
Migraine Epidemiology Insights
Migraine Epidemiology Segmentation
Migraine Market Outlook
The Migraine market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Migraine market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of Migraine market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, Migraine market in the 7MM is expected to change in the study period 2019-2032.
Learn more by requesting for sample @ Migraine Market
Migraine Key Companies
Table of Contents
Click here to read more about Migraine Market
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com